CN1387843A - Medicine for preventing and treating osteoporosis - Google Patents
Medicine for preventing and treating osteoporosis Download PDFInfo
- Publication number
- CN1387843A CN1387843A CN 01118284 CN01118284A CN1387843A CN 1387843 A CN1387843 A CN 1387843A CN 01118284 CN01118284 CN 01118284 CN 01118284 A CN01118284 A CN 01118284A CN 1387843 A CN1387843 A CN 1387843A
- Authority
- CN
- China
- Prior art keywords
- bone
- osteoporosis
- calcium
- glycine
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention is medicine for preventing and treating osteoporosis and is named calcium glycinate. Animal experiment shows that it can cure osteoporosis of white rat and speed heal of fracture of flap-eared white rabbit. Clinical application shows that it has its osteoporosis treating effect higher than estrogen, diphosphonate and Caltrate-D. It can raise elasticity and deformation and damage resistance of bone and reduce fracture possibility.
Description
Osteoporosis is that a class cause of disease is different but be the disease of common trait with the sclerotin net loss of unit volume, and its sign is the flags parameters that is reduced to of bone density.Suffer among this patient group, menopausal women accounts for important proportion, found this disease from nineteen forty-one Albright, and initiate treat with the estrogen replacement method after, up to the present, become the only resource with estrin treatment menopausal women osteoporosis, though it is unclear that this mechanism is still, the osteoporosis of estrin treatment menopausal women does not reach the purpose of healing, it only is the level of keeping when keeping treatment in other words, and a potential harm is very important, and that takes estrogen exactly may increase breast carcinoma, uterus carcinoma, the probability of cholelithiasis morbidity.For this reason, estrogenic use is restricted.
At present, treating osteoporotic another kind of medicine is diphosphate, and this medicine has used many restrictions, obeys and 2 weeks stops for 11 weeks, and the medicine of replenishing the calcium also will be eaten in the centre.If use badly, anti-road causes osteoporosis, our result of experiment, and curative effect is similar with estrogenic curative effect.
In recent years, begin to pay attention to Simvastatin medicine in the world, this medicine is the cardiopathic medicine of treatment originally, and it can attachedly help the treatment osteoporosis opportunity discovery of a chance.Therefore, caused the interest of many researcheres.But, our experiment confirm, Simvastatin is very ineffective to the curative effect of knochenbruch healing, much smaller than glycine chelated calcium.
People generally believe to replenish the calcium and can treat osteoporosis, perhaps prevention of osteoporosis.At present, the medicine of replenishing the calcium of Tui Jianing is exactly a calcium carbonate the most, and there are 16 kinds of calsium supplements in the U.S., wherein has 10 kinds to be to be raw material with the calcium carbonate.The true process of absorption of human body calcium it be unclear that, we think that absorption of human body calcium occurs in the small intestinal place, absorption of human body be calcium amino acid chelate, the quantity delivered of human body calcium deficiency and calcium does not have linear relationship, and the core of human body calcium deficiency is that intestinal secretion aminoacid deficiency causes (Science Bulletin 2000.45 (10)).Our experiment confirm replenishing the calcium merely, even is replenished the calcium in a large number, and the osteoporosis of treatment menopausal women is invalid.In the osseous tissue, postmenopausal osteoporosis influences most importantly bone trabecula, bone trabecula is some osteoid structures that are spongy or cavernous small size, it is inner interconnection and link to each other with hard and fine and close cortical bone, this cortex organizational composition the outer surface and the center backbone of bone, bone trabecular this crosslinked network structure has played the lateral support effect and has play a part crucial for whole biomechanical strength the outer cortical structure.So bone trabecular state is extremely important to the quality of skeleton.
Prevention of osteoporosis and treatment are of equal importance, and prevention good just can stop or postpone osteoporotic generation.But owing to causing that osteoporotic reason is a lot, prevention gets up to have a lot of difficulties.Before osteoporosis takes place, improve the quality of skeleton as far as possible, reduce or postpone osteoporotic generation, this is possible.
The glycine chelated calcium of our invention, molecular formula Ca (CH
2NH
2COO
-)
2Both can treat osteoporosis, the quality that improves bone be arranged, the character of prevention of osteoporosis again.
Glycine chelated calcium has the osteoporotic effect of treatment castration rat, almost reaches the level of healing.Its curative effect is better than estrogen and diphosphate greatly, and the contrast experiment confirms that Caltrate-D is of no curative effect.
Glycine chelated calcium, treatment menopausal women osteoporosis effective percentage is up to more than 70%.Caltrate-D is of no curative effect.
Glycine chelated calcium can promote the knochenbruch healing of large ear rabbit, and bone trabecula and medullary cavity are passed through in advance, and reach criterion of cure.
Glycine chelated calcium has improved the mechanical strength of the bone of large ear rabbit, has increased the elasticity of bone, has improved the anti-destruction of bone, the performance of resistance to deformation, has prevented osteoporosis.Its result is significantly better than Simvastatin.
The present invention refers to the pharmaceutical effect of calcium glycine, and this area professional prepares the compound of any non-effect or the medicine of attached helping property with calcium glycine as effective component, all should be considered as this
Within the scope of invention.
Claims (6)
1. one kind is used for prevention and treats osteoporotic medicine, and molecular formula is Ca (CH
2NH
2COO
-)
2H
2O.
2. the chemical compound in the claim 1, title is a glycine chelated calcium, molecular weight 206.08, electrical conductivity ∧=(46.6 ± 0.2) Ω Ca
-1Mol
-1
3. the chemical compound in the claim 1 is used for the treatment of the osteoporosis of menopausal women, obeys the 100-200mg glycine chelated calcium for each person every day, and effective percentage is at 60-70%.
4. the chemical compound in the claim 1, promptly glycine chelated calcium can promote the disconnected healing of bone, obeys the 100-200mg glycine chelated calcium for each person every day, bone trabecula can be carried and passing through the last week.
5. glycine chelated calcium has been used as effective component, has applied for that health food " executes close of bone ".
6. execute close of bone in the right 5, the heavy 300mg of sheet includes glycine chela calcium 100mg, and other is the attached material of no effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01118284 CN1387843A (en) | 2001-05-28 | 2001-05-28 | Medicine for preventing and treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01118284 CN1387843A (en) | 2001-05-28 | 2001-05-28 | Medicine for preventing and treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1387843A true CN1387843A (en) | 2003-01-01 |
Family
ID=4663075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01118284 Pending CN1387843A (en) | 2001-05-28 | 2001-05-28 | Medicine for preventing and treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1387843A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108125919A (en) * | 2018-02-12 | 2018-06-08 | 天津市索源化学生物技术有限公司 | A kind of glycine chelated calcium tablet composition and preparation method thereof |
| EP1789033B1 (en) * | 2004-08-09 | 2019-04-03 | Enrique Melendez Hevia | Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders |
-
2001
- 2001-05-28 CN CN 01118284 patent/CN1387843A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1789033B1 (en) * | 2004-08-09 | 2019-04-03 | Enrique Melendez Hevia | Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders |
| CN108125919A (en) * | 2018-02-12 | 2018-06-08 | 天津市索源化学生物技术有限公司 | A kind of glycine chelated calcium tablet composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2001118040A (en) | CONTROLED RELEASE COMPOSITION INCLUDING GNRH-II | |
| Thangavelu et al. | Myositis ossificans traumatica of the medial pterygoid | |
| CN1202130C (en) | Solid, stable and concentrated type ortho-silicis acid complex based on bio-absorption, and its prepn. method | |
| Tahmasebi et al. | The current regenerative medicine approaches of craniofacial diseases: A narrative review | |
| Rathe et al. | The effect of enamel matrix derivative (Emdogain®) on bone formation: a systematic review | |
| Barberi et al. | Bilateral cemento-ossifying fibroma of the maxillary sinus | |
| CN106213492A (en) | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density | |
| Krook et al. | Fluoride and alkaline phosphatase | |
| CN1387843A (en) | Medicine for preventing and treating osteoporosis | |
| CN1239893A (en) | Hormonal composition consisting of oestrogen compound and progestational compound | |
| CA2308532C (en) | Use of bisphosphonates for the treatment of osteogenesis imperfecta | |
| Millar et al. | A histological study of stainless steel and titanium screws in bone | |
| Sato et al. | Histological evaluation of alveolar ridge augmentation using injectable calcium phosphate bone cement in dogs | |
| Bang et al. | Allogenic demineralized dentin implants in jaw defects of Java monkeys | |
| US7374776B2 (en) | Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers | |
| Frasdsen | Effects of roentgen irradiation of the jaws on socket healing in young rats | |
| Sari et al. | Effectiveness of Anadara granosa shell-Stichopus hermanni granules at accelerating woven bone formation fourteen days after tooth extraction | |
| Yavuzer et al. | Fronto-orbital fibrous dysplasia | |
| CN1197561C (en) | Application of calcium L-threonate in treating cartilage related diseases | |
| CN101628112A (en) | Medicament composition for supplementing calcium | |
| CN1566086A (en) | Amino acid calcium chelate, preparation and application thereof | |
| JP2003095974A (en) | Composite medicine for safely stimulating osteoplasty | |
| CN1814282A (en) | Biological collagen oral liquor and preparing method | |
| Buchet et al. | Correction of malocclusion secondary to maxillary impaction fractures using a mandibular symphyseal realignment in eight cats | |
| JP6723562B2 (en) | Formulations for the regeneration of bone, cartilage, teeth, and periodontal tissue, and treatment of tumors and cysts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |